Drug design and discovery special interest group

 

What drug design and discovery is and why it's important

Drug design and discoveryThe process of the design/discovery of drugs typically involves understanding the character of targets (e.g. enzyme, cell, tissues, etc) related to the disease, setting-up the concept of drug design, providing lead compounds (via traditional medicines, natural products, biological macromolecules, compound libraries, computational chemistry, etc.), and design and lead optimisation by means of analysing structure-activity-relationships. A deep understanding of this process in addition to the mode of action at a molecular level will help pharmacists with decisions on appropriate dosing and administration of medicines.

Drugs play an important role in our world, not only as effective substances for the prevention, diagnosis and treatment of disease, but also to improve “quality of life”; enabling people to live with a disease as appropriate for their social and cultural background. When we discover or design a new drug, along with it comes great potential impact on life and quality of life.

 

About us and our objectives

Developing pharmaceutical sciences related to medicinal chemistry, and connecting pharmacists and pharmaceutical scientists from the point of view of drug design and discovery is the goal of this special interest group. Our objectives are to:

  • Provide discussion of pharmaceutical science related to medicinal chemistry
  • Educate pharmacists in drug discovery research and development
  • Provide up-to-date information and new findings on drug discovery
  • Collaborate on work related to pharmaceuticals and the environment

 

How we work

The special interest group is chaired by Prof. Takuya Kumamoto (Hiroshima University, Japan) and vice-chaired by Prof. Christopher McCurdy (University of Florida, USA).

     
Prof. Takuya Kumamoto     Prof. Christopher McCurdy

 

 

Activities

Our recent activities include:

 

Annual Report 2017

SIG Drug Design and Discovery aims to develop pharmaceutical sciences related to medicinal chemistry and to bridge pharmacists and pharmaceutical scientists on the viewpoint of drug design and discovery.  Starting point for the development of new drug is research works in medicinal chemistry.  On working in the area of medicinal chemistry, broad knowledge is necessary on organic chemistry in addition to biochemistry, molecular and structure biology, pharmacology, genetics, toxicology, computer technology, and related disciplines.  Process of the discovery of drugs typically involves understanding the character of target organs (enzyme, cell, tissues, etc) related to the disease, setting-up the concept of drug design, providing lead compounds (from traditional medicines, natural products, biological macromolecules, compound library, computational chemistry, etc.), drug design and lead optimization by means of the analysis of structure-activity-relationship.  Deep understanding of this process as well as the mode of action at a molecular level will help pharmacists to choose proper dosage and administration of drugs. 

Highlight of the year:

FIP PSWC 2017  Symposium C4
Responsible Supply Chains to Assure Global Health

Environmental impact of drug manufacturing (Takuya Kumamoto)
Pharmaceuticals in surface and ground water: Case in Nigeria (Olatunde James Olaitan)
Resilience and robustness of pharma supply chains (David Gonsalvez)
Bioeconomy - How to build human resource capacity in scientific research (Ahmed Fahmi)

Goals for 2018:

Goal #1: Providing the educational systems for pharmacists and students (SIG members) about research development of drugs design and discovery.
Goal #2: Providing the session for World Congress at Abu Dhabi meeting 2019.

 

Contact/Get involved

The starting point for developing a new drug is research work in medicinal chemistry. To work in medicinal chemistry, broad knowledge is needed: in organic chemistry, biochemistry, molecular and structural biology, pharmacology, genetics, toxicology, computer technology, and other disciplines. We welcome the participation of pharmaceutical scientists from widespread research areas in our discussions.

For more information about this special interest group or to get involved, please email Prof. Kumamoto: DrugDesignDiscovery@fip.org.